No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
VIR Vir Biotechnology
- 7.340
- -0.030-0.41%
Close Dec 20 16:00 ET
- 7.390
- +0.050+0.68%
Post 20:01 ET
1.01BMarket Cap-1.87P/E (TTM)
7.560High7.230Low3.75MVolume7.340Open7.370Pre Close27.48MTurnover4.05%Turnover RatioLossP/E (Static)137.72MShares13.09052wk High0.81P/B679.07MFloat Cap6.56052wk Low--Dividend TTM92.52MShs Float141.010Historical High--Div YieldTTM4.48%Amplitude6.560Historical Low7.337Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Vir Gets FDA Breakthrough Therapy Status for Two Drugs
Express News | Vir Biotechnology Inc - Phase 3 Eclipse Program to Begin in First Half of 2025
Express News | Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Loss-making Vir Biotechnology (NASDAQ:VIR) Has Seen Earnings and Shareholder Returns Follow the Same Downward Trajectory Over Past -80%
Heat List
US
Overall
Symbol
Price
% Chg
No Data